15128-90-2

Usage

Uses

Used in Chemical Synthesis:
3-Hydroxy-6-methyl-2-nitropyridine is used as an intermediate in the synthesis of various organic compounds, including 3-methoxy-6-methyl-2-nitropyridine. Its unique structure makes it a valuable building block for the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-hydroxy-6-methyl-2-nitropyridine is used as a starting material for the development of new drugs. Its molecular structure and properties make it a promising candidate for the synthesis of novel therapeutic agents, particularly in the areas of medicinal chemistry and drug design.
Used in Material Science:
3-Hydroxy-6-methyl-2-nitropyridine's unique chemical properties also make it a candidate for use in the development of new materials, such as polymers and coatings, with specific properties tailored for various applications in the material science industry.
Used in Analytical Chemistry:
The molecular structure and vibrational assignments of 3-hydroxy-6-methyl-2-nitropyridine have been investigated using density functional theory (DFT), making it a subject of interest in analytical chemistry. 3-HYDROXY-6-METHYL-2-NITROPYRIDINE can be used as a reference material for the development and validation of new analytical techniques and methods in the field.

InChI:InChI=1/C6H6N2O3/c1-4-2-3-5(9)6(7-4)8(10)11/h2-3,9H,1H3

Upstream product

• 42097-42-7 3-hydroxy-2-hydroxymethyl-6-methylpyridine 
• 1121-78-4 5-Hydroxy-2-methylpyridine 

Downstream Products

• 24015-98-3 3-methoxy-6-methyl-2-nitro-pyridine 
• 20348-16-7 2-amino-3-hydroxy-6-methylpyridine 
• 155790-03-7 2-amino-3-methylamino-6-methyl-pyridine 
• 155789-81-4 2-amino-1,5-dimethylimidazo<4,5-b>pyridine 
• 1355026-33-3 C₁₇H₁₆Cl₂N₂O₄ 
• 1355026-29-7 C₁₅H₁₄Cl₂N₂O₄ 
• 1355026-32-2 C₁₄H₁₀Cl₂N₂O₅ 
• 1355026-31-1 C₁₄H₁₂Cl₂N₂O₃ 
• 1355026-30-0 C₁₅H₁₄Cl₂N₂O₃ 
• 1355026-16-2 C₁₅H₁₅ClN₂O₅ 
• 1355026-18-4 C₁₅H₁₅ClN₂O₅ 
• 1355026-20-8 C₁₆H₁₈N₂O₄ 
• 1355026-22-0 C₁₄H₁₂ClFN₂O₄ 
• 1355026-23-1 C₁₄H₁₂ClFN₂O₄ 

Relevant academic research and scientific papers

Iodine(III)-Catalyzed Electrophilic Nitration of Phenols via Non-Br?nsted Acidic NO2+ Generation

The first catalytic procedure for the electrophilic nitration of phenols was developed using iodosylbenzene as an organocatalyst based on iodine(III) and aluminum nitrate as a nitro group source. This atom-economic protocol occurs under mild, non-Br?nsted acidic and open-flask reaction conditions with a broad functional-group tolerance including several heterocycles. Density functional theory (DFT) calculations at the (SMD:MeCN)Mo8-HX/(LANLo8+f,6-311+G) level indicated that the reaction proceeds through a cationic pathway that efficiently generates the NO2+ ion, which is the nitrating species under neutral conditions.

PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS

This invention relates to imidazopyridylmethylene substituted piperidine derivatives orexin antagonists and their use as pharmaceuticals.

3-Pyridyl enantiomers and their use as analgesics

The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: STR1 or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

SYNTHESIS OF THE MUTAGENIC 2-AMINO-1,6-DIMETHYLIMIDAZOPYRIDINE (1,6-DMIP) AND FIVE OF ITS ISOMERS

Synthetic routes to 2-amino-1,6-dimethylimidazopyridine and its 1,5-, 1,7-, 3,5- 3,6- and 3,7-dimethyl isomers from methyl derivatives of 3-hydroxy- or 2-amino-pyridine and 2-chloronicotinic acid are described.

Medicinal oxazolopyridine compounds

Compounds of general formula (I): STR1 in which: R1 and R2 each represent a hydrogen atom or, with the nitrogen and oxygen which bear them, form an --O--CO--N link, W represents a halogen atom or a lower alkyl or alkoxy group optionally substituted with one or more halogen atoms, such as trifluoromethyl, and m being between 0 and 3, A is a linear or branched alkyl radical comprising from 1 to 6 carbon atoms, R3 and R4 are defined in the description have medicinal properties.

Oxazolopyridine compounds

Compounds of general formula (I): STR1 in which: R1 and R2 each represent a hydrogen atom or, with the oxygen and nitrogen, form an --O--CO--N-- linkage, W represents a halogen atom or a lower alkyl or alkoxy group optionally substituted with one or more halogen atoms, such as trifluoromethyl, and m being between 0 and 3, A represents a linear or branched lower alkylene group, and Ar represents an aryl or heteroaryl group optionally substituted with one or more halogen atoms or with one or more lower alkyl, hydroxy, hydroxysulfonyloxy, lower alkoxy or aryloxy groups optionally substituted with one or more halogen atoms, such as a trifluoromethyl group, on the understanding that lower alkyl or lower alkyloxy radical is understood to mean a linear or branched alkyl group comprising from 1 to 6 carbon atom, their isomers, epimers and diastereoisomers. Medicinal products useful in the treatment of pain.

Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazolpyridines and Analogues

The search for a successor to 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazopyridine, Sch 28080 (27), a compound that exhibits gastric antisecretory and cytoprotective properties and has undergone clinical evaluation as an antiulcer agent, has culminated in the identification of four related compounds that exhibit pharmacologic profiles similar to that of 27.In three of these potential successors an amino group functions as a surrogate for the 3-cyanomethyl substituent of the prototype.The present work concerns, in addition to an evaluation of the structure-activity relationships of a series of analogues of 27, preliminary studies of the pharmacodynamics and metabolism of 27, performed with the aid of cyano carbon labeled versions of the drug (13C labeled; 28; 14C labeled, 29).These studies have shown that 27 is well-absorbed and extensively metabolized and that the major metabolite of 27 is the thiocyanate anion.A similar study performed on 3-amino-2-methyl-8-(phenylmethoxy)imidazopyridine, labeled at the 3-position with carbon-13 (41) or carbon-14 (42), revealed that this compound, which has an antisecretory/cytoprotective profile comparable to that of 27, is also metabolized to thiocyanate anion, although this must occur via a different mechanism.The chemistry section includes a discussion of the potential sites of protonation of the pharmacologically similar 3-amino analogue 40 and the structurally related imidazopyrazine 67.Predictions based on charge density and protonation product stabilities are presented.That N1 is the site of protonation in these analogues has been definitively demonstrated by X-ray crystal structure analysis, which alsounequivocally established the assigned imidazopyrazine ring structure.

Anti-inflammatory oxazole[4,5-b]pyridines

The various isomers of oxazolo- and thiazolopyridines having utility as antiinflammatory, antipyretic and analgesic agents are prepared by condensation of an appropriate amino-hydroxypyridine or amino-mercaptopyridine with a carboxylic acid, halide or anhydride.